164 related articles for article (PubMed ID: 37448573)
1.
Prabhakaran P; Hebbani AV; Menon SV; Paital B; Murmu S; Kumar S; Singh MK; Sahoo DK; Desai PPD
Front Microbiol; 2023; 14():1194794. PubMed ID: 37448573
[TBL] [Abstract][Full Text] [Related]
2. Identification of potential bioactive natural compounds from Indonesian medicinal plants against 3-chymotrypsin-like protease (3CL
Prasetyo WE; Purnomo H; Sadrini M; Wibowo FR; Firdaus M; Kusumaningsih T
J Biomol Struct Dyn; 2023 Jul; 41(10):4467-4484. PubMed ID: 35470785
[TBL] [Abstract][Full Text] [Related]
3. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation.
Bepari AK; Reza HM
PeerJ; 2021; 9():e11261. PubMed ID: 33954055
[TBL] [Abstract][Full Text] [Related]
5. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.
Roy R; Sk MF; Jonniya NA; Poddar S; Kar P
J Biomol Struct Dyn; 2022 Sep; 40(14):6556-6568. PubMed ID: 33682642
[TBL] [Abstract][Full Text] [Related]
6. Identification of medicinal plant-based phytochemicals as a potential inhibitor for SARS-CoV-2 main protease (M
Hossain A; Rahman ME; Rahman MS; Nasirujjaman K; Matin MN; Faruqe MO; Rabbee MF
Comput Biol Med; 2023 May; 157():106785. PubMed ID: 36931201
[TBL] [Abstract][Full Text] [Related]
7. "Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CL
Bhowmik D; Sharma RD; Prakash A; Kumar D
J Mol Struct; 2021 Jun; 1233():130094. PubMed ID: 33612858
[TBL] [Abstract][Full Text] [Related]
8. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.
Yadav R; Imran M; Dhamija P; Chaurasia DK; Handu S
J Biomol Struct Dyn; 2021 Oct; 39(17):6617-6632. PubMed ID: 32715956
[TBL] [Abstract][Full Text] [Related]
9. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
Abdizadeh R; Hadizadeh F; Abdizadeh T
Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
[TBL] [Abstract][Full Text] [Related]
10. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
[TBL] [Abstract][Full Text] [Related]
11. Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening.
Abdusalam AAA; Murugaiyah V
Front Mol Biosci; 2020; 7():603037. PubMed ID: 33392261
[TBL] [Abstract][Full Text] [Related]
12. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
[TBL] [Abstract][Full Text] [Related]
13. Virtual screening and molecular simulation study of natural products database for lead identification of novel coronavirus main protease inhibitors.
Tripathi N; Goel B; Bhardwaj N; Sahu B; Kumar H; Jain SK
J Biomol Struct Dyn; 2022 May; 40(8):3655-3667. PubMed ID: 33213294
[TBL] [Abstract][Full Text] [Related]
14. Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PL
Verma D; Mitra D; Paul M; Chaudhary P; Kamboj A; Thatoi H; Janmeda P; Jain D; Panneerselvam P; Shrivastav R; Pant K; Das Mohapatra PK
Curr Res Pharmacol Drug Discov; 2021; 2():100038. PubMed ID: 34870149
[TBL] [Abstract][Full Text] [Related]
15.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
16. Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation.
Elekofehinti OO; Iwaloye O; Molehin OR; Famusiwa CD
In Silico Pharmacol; 2021; 9(1):49. PubMed ID: 34395160
[TBL] [Abstract][Full Text] [Related]
17. Binding and inhibitory effect of ravidasvir on 3CL
Bera K
J Biomol Struct Dyn; 2022 Oct; 40(16):7303-7310. PubMed ID: 33682639
[TBL] [Abstract][Full Text] [Related]
18.
Iype E; Pillai U J; Kumar I; Gaastra-Nedea SV; Subramanian R; Saha RN; Dutta M
J Biomol Struct Dyn; 2022; 40(23):12800-12811. PubMed ID: 34550861
[TBL] [Abstract][Full Text] [Related]
19. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
[TBL] [Abstract][Full Text] [Related]
20. QSAR modeling and pharmacoinformatics of SARS coronavirus 3C-like protease inhibitors.
Ishola AA; Adedirin O; Joshi T; Chandra S
Comput Biol Med; 2021 Jul; 134():104483. PubMed ID: 34020129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]